Literature DB >> 6696324

Nighttime ventilation improves respiratory failure in secondary kyphoscoliosis.

V H Hoeppner, D W Cockcroft, J A Dosman, D J Cotton.   

Abstract

Four patients with cardiorespiratory failure caused by secondary kyphoscoliosis were studied. Polycythemia, cor pulmonale, restrictive lung pattern (functional residual capacity (FRC), 17 to 27% predicted; vital capacity (VC), 11 to 23% predicted), and abnormal arterial blood gases, primarily hypoventilation (PaO2, 31 to 44 mm Hg; PaCO2, 52 to 73 mm Hg), were seen in all. Supplementary oxygen, digoxin, diuretics, 15 min of intermittent positive-pressure breathing with inspired pressure (PI) 25 cm H2O 4 times daily, and tracheostomy failed to produce improvement. However, 12 h of nighttime ventilation (NTV) with PI 28 to 35 cm H2O through a permanent tracheostomy proved effective. Within 72 h, dyspnea at rest, restless sleep, and frequent waking resolved. Within 8 to 22 days, the PaO2 was approximately 58 mmHg and the PaCO2 was approximately 41 mm Hg while breathing 21% oxygen spontaneously during the day. The right heart failure resolved within 2 to 7 wk, and the hemoglobin count decreased to approximately 165 g/L within 2 to 6 months. There was a mean increase of 700 ml (72%) in functional residual capacity and 430 ml (49%) in vital capacity. The patients were discharged 2 days to 5 wk after NTV commenced. Daytime activity increased, approaching a normal life style. The improvement was sustained over a mean follow-up period of 3.4 yr. Problems included recurrent episodes of tracheobronchitis, mild self-limiting hemoptysis, and speech modification. Nighttime ventilation may be an effective alternative for long-term treatment of cardiorespiratory failure caused by secondary kyphoscoliosis.

Entities:  

Mesh:

Year:  1984        PMID: 6696324

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  11 in total

1.  Respiratory medicine in Saskatchewan: An historical perspective.

Authors:  Donald W Cockcroft
Journal:  Can Respir J       Date:  2015 Jul-Aug       Impact factor: 2.409

2.  Nocturnal positive-pressure nasal ventilation for respiratory failure during pregnancy.

Authors:  D A McKim; R E Dales; G G Lefebvre; M Proulx
Journal:  CMAJ       Date:  1988-12-01       Impact factor: 8.262

3.  Respiratory failure and sleep in neuromuscular disease.

Authors:  P T Bye; E R Ellis; F G Issa; P M Donnelly; C E Sullivan
Journal:  Thorax       Date:  1990-04       Impact factor: 9.139

4.  Long term non-invasive ventilation in the community for patients with musculoskeletal disorders: 46 year experience and review.

Authors:  A Baydur; E Layne; H Aral; N Krishnareddy; R Topacio; G Frederick; W Bodden
Journal:  Thorax       Date:  2000-01       Impact factor: 9.139

Review 5.  Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall disorders.

Authors:  Djillali Annane; David Orlikowski; Sylvie Chevret
Journal:  Cochrane Database Syst Rev       Date:  2014-12-13

6.  Bystander effects induced by electron beam-irradiated MCF-7 cells: a potential mechanism of therapy resistance.

Authors:  Maryam Feghhi; Jafar Rezaie; Kamal Mostafanezhad; Nasrollah Jabbari
Journal:  Breast Cancer Res Treat       Date:  2021-05-27       Impact factor: 4.872

7.  Treatment of respiratory failure due to kyphoscoliosis with nasal intermittent positive pressure ventilation (NIPPV).

Authors:  G Finlay; D Concannon; T J McDonnell
Journal:  Ir J Med Sci       Date:  1995-01       Impact factor: 1.568

8.  Long term non-invasive domiciliary assisted ventilation for respiratory failure following thoracoplasty.

Authors:  M Jackson; I Smith; M King; J Shneerson
Journal:  Thorax       Date:  1994-09       Impact factor: 9.139

Review 9.  Mechanisms and management of central sleep apnea.

Authors:  P J Hanly
Journal:  Lung       Date:  1992       Impact factor: 2.584

10.  Control of nocturnal hypoventilation by nasal intermittent positive pressure ventilation.

Authors:  N Carroll; M A Branthwaite
Journal:  Thorax       Date:  1988-05       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.